ClinicalTrials.gg
RecruitingNCT07342036LITRUpdated Jan 16, 2026

Prospective Study of Lead-associated Tricuspid Regurgitation in Patients Undergoing New Transvalvular Lead Insertion

An observational study in Tricuspid Valve Regurgitation, Pacemaker and ICD, sponsored by Hazem Omran. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-16.

Sponsored by Hazem Omran · Observational

How we know

From the registry’s dates

  • Started Jul 2024; still recruiting 2 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 51 studies in Tricuspid Valve Insufficiency with a site in Germany — 24 open to participants now, 31 under way, none of them phase 3. Tricuspid Valve Insufficiency · Germany.

Planned enrollment
18th of 26
200 · median 506
Started
2024
with 4 others
Observational
26 of 51
17 open now
Primary completion
2027-01
later than 17 of 30 live
Registered
49th of 51
by date

Among the 51 studies in Tricuspid Valve Insufficiency with a site in Germany, this one is the 18th largest by planned enrollment of the 26 observational ones that give a count, is one of 5 that started in 2024, is one of 26 observational ones, reaches primary completion later than 17 of the 30 other live ones, and was the 49th registered.

Tricuspid Valve Insufficiency

229 studies on the registry are indexed under Tricuspid Valve Insufficiency; 111 are open to participants now.

Browse Tricuspid Valve Insufficiency studies →

Open to participants now

24 of the 51 studies in Tricuspid Valve Insufficiency with a site in Germany are open now. Recruiting first, the newest first:

18 more — sign in →

All 24 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 81 Tricuspid Valve Insufficiency studies recruiting now, 67 (83%) set no upper age limit and none (0%) stop at 75 or younger; 7 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies in Tricuspid Valve Insufficiency with a site in Germany, or all of them as a file.
02

Study summary

The goal of this clinical trial is to record the incidence of newly developed or worsening tricuspid valve regurgitation (TR) following the implantation of a pacemaker or defibrillator with a transvenous lead. To collect this data, a transthoracic echocardiogram (TTE) with 3D imaging of the tricuspid valve (TV) will be performed before and after pacemaker implantation, with particular emphasis on assessing the tricuspid valve. Additionally, routine follow-up visits will be conducted at 6 and 12 months post-intervention, during which a TTE, ECG, NT-proBNP measurement, and pacemaker check will be performed.

Read the detailed description

The prevalence of tricuspid regurgitation (TR) in patients with a pacemaker or ICD/CRT device varies widely, ranging from 5% to 45% across different study protocols. To date, only retrospective analyses have shown that implantation of a device with a transvalvular lead can cause or worsen TR, highlighting the importance of early diagnosis. The aim of this study is to prospectively evaluate patients indicated for cardiac electronic device implantation to document the incidence of newly developed regurgitation (greater than trace) or worsening of existing regurgitation (by at least one grade). Additionally, the study will investigate predictive factors for the development or progression of TR.

03

Conditions studied

  • Tricuspid Valve Regurgitation
  • Pacemaker
  • ICD
  • Left Bundle Branch Area Pacing

Keywords

  • tricuspid regurgitation
  • lead-related TR
  • lead-associated TR
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

patients who have been indicated to have a new cardiac device with a transvalvular probe implanted for any given indication

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • medically indicated for pacemaker, ICD- or CRT implantation
  • No previous diagnosis of severe tricuspid regurgitation on enrollment
  • No existing transvalvular device (must be first implantation)
  • No other diagnosed severe valvular heart disease
  • Not previous diagnosis with pre-capillary pulmonary hypertension
  • No previous diagnosis of structural disease of the right ventricle (i.e. ACM, cardiac sarcoidosis, carcinoid...)

Exclusion criteria

Exclusion Criteria:

  • Patients unable to give consent
  • Under the age of 18 years
  • Relevant pre-capillary pulmonary hypertension according to decision of the heart-team (sPAP echo >70 mmHg)
  • Severe tricuspid valve regurgitation (Grade 3 or worse) on enrollment
  • Patients who have undergone Lead-explantation
  • Exisiting valvular heart disease requiring treatment according to the decision of the heart-team. These patients may be enrolled in the study following treatment.
  • Previous tricuspid valve surgery
  • Patients with congenital heart disease (i.e. tetralogy of fallot, Ebstein's anomaly,...)
  • Pregnant or breastfeeding women
  • \< 12 months
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (estimated)
Target follow-up
1 Year
Patient registry
Yes

Groups and cohorts

  • Pacemaker-standard

    Only pacemaker with standard positioning (no ICD leads, no LBBaP)

  • ICD

    any ICD leads through tricuspid valve

  • LBBaP

    Left bundle branch area pacing leads

06

What researchers measure

Primary outcomes

  1. Worsening of TR of at least 1 grade

    Worsening of tricuspid regurgitation of at least one grade from baseline before lead insertion through tricuspid valve

    Time frame: over the sutdy period up to 1 year after lead insertion

Secondary outcomes

  1. TR > mild at follow-up

    The percentage of patients with at least moderate TR or worse

    Time frame: during study time frame up to 1 year after Pacemaker/ICD implantation

  2. NTproBNP change from baseline

    Change in NTproBNP levels from baseline to 6 and 12 Months

    Time frame: at 6 and at 12 months after Pacemaker/ICD implantation

  3. Hospitalization for heart failure (HFH)

    Any uplanned hopsitalization with requirement of iv diuretics therapy after inclusion

    Time frame: up to 12 months after Pacemaker/ICD implantation

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Jan 2027, 29 months after the start.

Of 47 observational studies under Tricuspid Valve Insufficiency, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 106. This study's planned 29 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 6, 2026
First posted
Jan 15, 2026
StartActual
Jul 19, 2024
Primary completionEst.
Jan 1, 2027
CompletionEst.
Jan 30, 2027
Last update
Jan 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07342036
Lead sponsor
Hazem Omran
Responsible party
Hazem Omran (Attending Physician, Clinic for General and Interventional Cardiology/Angiology, Herz- und Diabeteszentrum NRW) — Sponsor-investigator
First posted
Jan 15, 2026
Start date
Jul 19, 2024
Primary completion
Jan 1, 2027 (estimated)
Completion
Jan 30, 2027 (estimated)
Last update
Jan 16, 2026

Study contacts

Hazem Omran, MD
Contact
homran@hdz-nrw.de
+49 5731 970
Lena Riemke-Maw, BSc
Contact
lriemke-maw@hdz-nrw.de
+49 5731 97 ext. 1258
Hazem Omran, MD
principal investigator · Herz- und Diabeteszentrum NRW

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion